Bisphosphonates as a Countermeasure to Space Flight Induced Bone Loss (Bisphosphonates) - 12.31.14
ISS Science for Everyone
Science Objectives for Everyone
The purpose of the Bisphosphonates as a Countermeasure to Space Flight Induced Bone Loss study is to determine whether an antiresorptive agent, in conjunction with the routine in-flight exercise program, protects International Space Station (ISS) crewmembers from the regional decreases in bone mineral density documented on previous ISS missions.
Science Results for Everyone
ISS crew members exercise regularly to help reduce bone loss but still lose signifcant bone mass over a long mission. A weekly pill may help. The Bisphosphonates as a Countermeasure to Space Flight Induced Bone Loss study tests biphosphonates, bone antiresorptive agents used to increase bone strength, in conjunction with routine in-flight exercise during long-term spaceflight. Bone measurements and comparisons of early model resistance exercise device or the advanced resistance exercise device (ARED) show that ARED and bisphosphonate together improve essentially all measures of bone physiology during spaceflight. Scientists conlude that exercise plus an antiresoptive drug may help prevent bone loss on long missions.
NASA Johnson Space Center, Human Research Program, Houston, TX, United States
Sponsoring Space Agency
National Aeronautics and Space Administration (NASA)
Human Exploration and Operations Mission Directorate (HEOMD)
ISS Expedition Duration
October 2008 - Ongoing
Previous ISS Missions
- The potential for loss of bone mass is one of the most important medical concerns for long-duration manned space flight with regional losses of 1 to 2 percent per month in spite of the fact that crewmembers exercise while in space. The resultant hypercalciuria (abnormally high calcium levels in urine) increases the risk of renal stone formation.
- Bisphosphonates are a group of antiresorptive agents that block the breakdown of bone and are used to treat osteoporosis and other disorders related to bone turnover.
- This study tests the effectiveness of alendronate, taken as a pill once per week before and during space flight.
- If shown to be an effective countermeasure to space flight-induced bone loss, bisphosphonates or other antiresorptive agents could help prevent several bone-related problems for crewmembers on the International Space Station (ISS) and on future long-duration missions. These problems include loss of bone mineral mass and strength and the possibility of developing renal stones during or after space flight.
The purpose of this investigation is to determine whether bisphosphonates, in conjunction with the routine in-flight exercise program, protects International Space Station (ISS) crewmembers from the regional decreases in bone mineral density documented on previous ISS flights. Two dosing regimens were originally planned, an oral dose of 70 mg of alendronate taken weekly starting 3 weeks prior to flight and then throughout the flight and an intravenous (I.V.) dose of zoledronic acid, 4 mg, administered just once approximately 45 days before flight. However, only alendronate administration was actually tested. Control subjects, who participate in all pre-, in-, and post-flight tests, but do not ingest an antiresorptive agent, were added to control for the effects of improved exercise equipment aboard the ISS.
An interim review of the data for this study (04-E255/SMO 021) indicated that it was necessary to add a new control group whose results could be compared to those of crewmembers who have taken bisphosphonates. The original historical control group (14 crewmembers from early ISS flights) exercised using the Interim Resistive Exercise Device (IRED), while the bisphosphonate subject group (7 subjects, now complete) exercised on the newer Advanced Resistive Exercise Device (ARED). The new control group will help distinguish the relative effects of bisphosphonates versus the confounder of ARED. The control subjects will participate in essentially the same data collection protocol as the bisphosphonate group, but will not take the oral or i.v. bisphosphonate.
The primary measurement objective of this study is to obtain preflight and postflight Quantitative Computed Tomography (QCT) scans of the hip. The QCT scans provide volumetric bone density information of both cortical and trabecular (spongy) bone regions of the hip. This study aims to show that bisphosphonates significantly reduces bone mineral density loss and the increased risk of renal stone formation documented previously on untreated ISS crewmembers.
Secondary measurement objectives include: preflight and postflight Dual-energy X-Ray Absorptiometry (DXA) scans of the whole body, spine, hip, and heel; preflight and postflight scans of the tibia using peripheral Quantitative Computed Tomography (pQCT); preflight and postflight abdominal/retroperitoneal ultrasound scans; preflight and postflight blood draws to measure serum markers of bone metabolism, and preflight, in flight, and postflight urine collections to measure urinary markers of bone metabolism. Urine measurements are also used to look at the risk for developing renal stones before, during and after flight.
The purpose of this investigation is to determine whether antiresorptive bisphosphonates, in conjunction with the routine in-flight exercise program, will protect ISS crewmembers from the regional decreases in bone mineral density and bone strength documented on previous ISS flights. If shown to be an effective countermeasure to space flight induced bone loss, bisphosphonates could prevent or ameliorate several potential bone-related problems identified in NASA's Critical Path Roadmap. If bisphosphonates improve the efficiency of in-flight exercise to maintain bone mass, then more crew time could be made available for other purposes.
The benefits of this research are primarily for space travelers. Knowledge gained from this investigation may generate useful information applicable to patients on Earth with accelerated bone loss due to disuse (e.g., spinal cord injury patients or those with prolonged immobilization).
This experiment requires the participation of long-duration crewmembers taking the drug compared with 10 control subjects. All subjects will complete DXA scans (Launch minus 45 days (L-45), Return plus 5 days (R+5), R+180, [not required for controls], and R+360), pQCT scans (L-45, R+5, R+180, [not required for controls], and R+360), high resolution QCT scans (L-45, R+5, R+360), ultrasound scans (L-180, R+30), 24-hr urine collections (L-45, R+0, early inflight, midflight, late inflight, R+30, R+360), and blood draws (L-45, R+0, R+30, and R+360). Alendronate subjects will complete an Alendronate Tolerance Test on L-180, and they will take Alendronate on L-17, L-10, and L-3.
While in flight, Alendronate subjects ingest one pill weekly. All subjects conduct three urine collection sessions (4 weeks, 12 weeks, and 24 weeks). Crewmembers also take a daily Vitamin D supplement for the duration of the mission.
Seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS are given an oral dose of 70 mg of alendronate (a bisphosphonate drug used to treat the thinning of bone, i.e. osteoporosis) weekly starting 3 weeks before flight and continuing throughout the mission to study the effectiveness of alendronate on reducing bone loss. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Bone assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. In addition to pre- and post-flight measurements, these results are compared to data from 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and 11 ISS astronauts who exercised using the newer Advanced Resistance Exercise Device (ARED). Findings indicate that the ARED provided significant lessening of bone loss compared with the older device although some post-flight decreases in the femur neck and hip remained. The combination of ARED and bisphosphonate lessen the expected decline in essentially all indices of altered bone physiology during spaceflight. Losses in bone mineral density of the spine, hip, and pelvis, as well as measurements of fall and stance bone strength of the hip, bone resorption markers, and urinary calcium show that the combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration space flight.
LeBlanc AD, LeBlanc AD, Matsumoto T, Jones JA, Shapiro J, Shapiro J, Lang TF, Shackelford LC, Smith SM, Smith SM, Evans HJ, Spector ER, Ploutz-Snyder RJ, Sibonga JD, Keyak JH, Nakamura T, Kohri K, Ohshima H. Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. Osteoporosis International. 2013 July; 24(7): 2105-2114.
Ground Based Results Publications
Shapiro J, Shapiro J, Beck TJ, Mustapha B, Ruff CB, Ballard P, Brintzenhofescoz K, Caminis J. Zoledronic Acid Counteracts Bone Loss in the Spinal Cord Injury Model of Microgravity. Journal of Bone and Mineral Research. 2004; 19: S445.
LeBlanc AD, LeBlanc AD, Schneider VS, Shackelford LC, West S, Oganov VS, Bakulin AV, Voronin L. Bone Mineral and lean tissue loss after long duration spaceflight. Journal of Musculoskeletal and Neuronal Interactions. 2000; 1(2): 157-160.
Bone HG, Hosking D, Devogelaer J, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New England Journal of Medicine. 2004; 350(12): 1189-1199.
LeBlanc AD, LeBlanc AD, Driscoll TB, Shackelford LC, Evans HJ, Rianon NJ, Smith SM, Smith SM, Feeback DL, Lai D. Alendronate as an Effective Countermeasure to Disuse Induced Bone Loss. Journal of Musculoskeletal and Neuronal Interactions. 2002; 2(4): 335-343.
Watanabe Y, Ohshima H, Mizuno K, Sekiguchi C, Fukunaga M, Kohri K, Rittweger J, Felsenberg D, Matsumoto T, Nakamura T. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. Journal of Bone and Mineral Research. 2004; 19(11): 1771-1778.
One mm thick sections through the mid frontal plane of the hip, showing regions of evaluation in white superimposed on a false color image of the Quantitative Computed Tomography (QCT) data. The left hand image shows the cortical region of the femoral neck and the right hand image shows the trabecular bone regions. Courtesy image of NASA.
+ View Larger Image